Compare Danaher Corporation (DHR) vs Procter & Gamble Co (PG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Danaher Corporation vs Procter & Gamble Co — how do they compare? Danaher Corporation trades at $217.88 (market cap $153.60B), while Procter & Gamble Co trades at $150.35 (market cap $349.77B). The key difference: Procter & Gamble Co is far larger — about 2.3× Danaher Corporation's market cap, and Procter & Gamble Co pays the higher dividend (2.89%). Which is the better fit depends on your goals — on Pluang, investors hold Danaher Corporation for 69 Days and Procter & Gamble Co for 131 Days on average.
| DHR | PG | |
|---|---|---|
Market Cap | $153.60B | $349.77B |
Volume | 3,974,063 | 10,055,825 |
Sector | Health | Consumer Staples |
52-Week High | $242.05 | $167.18 |
52-Week Low | $161.91 | $138.10 |
Typical Hold Time | 69 Days | 131 Days |
Enterprise Value | $175.81B | $375.61B |
Dividend Yield | 0.73% | 2.89% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Danaher (DHR) trades at $217.46, up 0.88% on the day, with a bullish technical signal from moving averages and strong analyst support. The company has consistently beaten earnings estimates in recent quarters, with Q3 2026 results pending. Revenue grew to $24.57B in 2025, though net margins have compressed from historical highs. A quarterly dividend of $0.40 was declared, payable in October 2026.
The outlook remains positive given earnings momentum and institutional accumulation, but valuation multiples are elevated. Risks include margin pressure and high capital expenditure in 2026. The consensus price target of $230.31 implies modest upside, supported by 70% buy ratings from analysts.
Procter & Gamble (PG) trades at $147.82, down 0.4% on the day, with a bullish technical signal from moving averages and neutral oscillators. The company reported consistent earnings beats in recent quarters, with Q3 2026 EPS expected at $1.88. Strong fundamentals include $84.28B revenue, 18.44% net margin, and robust cash flow generation. Recent developments include a WNBA partnership and a dividend declaration of $1.09 payable in August 2026.
PG offers stable growth with premium valuation metrics (P/E 22.33, P/S 4.11) supported by strong brand equity and dividend consistency. Risks include premium valuation concerns amid modest growth outlook and competitive pressures. Analyst consensus is bullish with a $160.13 price target, though near-term upside may be limited given current price proximity to the lower target range.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Danaher Corporation
In 1984, Danaher's founders transformed a real estate organization into an industrial-focused manufacturing company. Through a series of mergers, acquisitions, and divestitures, including the Fortive separation in 2016, Danaher now focuses primarily on manufacturing scientific instruments and consumables in three segments: life sciences, diagnostics, and environmental and applied solutions. In late 2019, Danaher separated from its dental business through an initial public offering process, and in early 2020, it acquired GE's Biopharma business, now called Cytiva, which added to its life sciences segment.
Read more on DHR →About Procter & Gamble Co
The Procter & Gamble Company manufactures and markets consumer products in countries throughout the world. The Company provides products in the laundry and cleaning, paper, beauty care, food and beverage, and health care segments. Procter & Gamble products are sold primarily through mass merchandisers, grocery stores, membership club stores, drug stores, and neighborhood stores.
Read more on PG →
